Bile Duct Neoplasms

Displaying 1 - 13 of 13CSV
Schönherr, H., Ayaz, P., Taylor, A. M., Casaletto, J. B., Touré, B. B., Moustakas, D. T., Hudson, B. M., Valverde, R., Zhao, S., O’Hearn, P. J., Foster, L., Sharon, D. A., Garfinkle, S., Giordanetto, F., Lescarbeau, A., Kurukulasuriya, R., Gerami-Moayed, N., Maglic, D., Bruderek, K., … Bergstrom, D. A. (2024). Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences, 121(6). https://doi.org/10.1073/pnas.2317756121
Publication Date
Hassan, H., Chakrabarti, S., Zemla, T., Yin, J., Wookey, V., Prasai, K., Abdellatief, A., Katta, R., Tran, N., Jin, Z., Cleary, S., Roberts, L., & Mahipal, A. (2023). Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. European Journal of Surgical Oncology, 49(11), 106994. https://doi.org/10.1016/j.ejso.2023.106994
Publication Date
Subbiah, V., Sahai, V., Maglic, D., Bruderek, K., Touré, B. B., Zhao, S., Valverde, R., O’Hearn, P. J., Moustakas, D. T., Schönherr, H., Gerami-Moayed, N., Taylor, A. M., Hudson, B. M., Houde, D. J., Pal, D., Foster, L., Gunaydin, H., Ayaz, P., Sharon, D. A., … Casaletto, J. B. (2023). RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations. Cancer Discovery, 13(9), 2012–2031. https://doi.org/10.1158/2159-8290.cd-23-0475
Publication Date
Suben, J., Goyal, A., Rao, R., & Sung, S. (2023). Diagnostic implication of extracellular mucin in pancreatic/biliary brushing and stent cytology. Cancer Cytopathology, 131(6), 360–364. Portico. https://doi.org/10.1002/cncy.22685
Publication Date
Martin-Serrano, M. A., Kepecs, B., Torres-Martin, M., Bramel, E. R., Haber, P. K., Merritt, E., Rialdi, A., Param, N. J., Maeda, M., Lindblad, K. E., Carter, J. K., Barcena-Varela, M., Mazzaferro, V., Schwartz, M., Affo, S., Schwabe, R. F., Villanueva, A., Guccione, E., Friedman, S. L., … Sia, D. (2022). Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut, 72(4), 736–748. https://doi.org/10.1136/gutjnl-2021-326514
Publication Date
Singal, A. G., Ghaziani, T. T., Mehta, N., Zhou, K., Grinspan, L. T., Benhammou, J. N., Moon, A. M., Yang, J. D., Salgia, R., Pillai, A., Zheng, E., Rich, N. E., Gopal, P., Jalal, P., Verna, E., Yekkaluri, S., Phen, S., Melendez-Torres, J., Alshuwaykh, O., … Parikh, N. D. (2023). Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatology Communications, 7(3). https://doi.org/10.1097/hc9.0000000000000073
Publication Date
Gholami, S., Colby, S., Horowitz, D. P., Guthrie, K. A., Ben-Josef, E., El-Khoueiry, A. B., Blanke, C. D., Philip, P. A., Kachnic, L. A., Ahmad, S. A., & Rocha, F. G. (2023). Adjuvant Chemoradiation in Patients with Lymph Node-Positive Biliary Tract Cancers: Secondary Analysis of a Single-Arm Clinical Trial (SWOG 0809). Annals of Surgical Oncology, 30(3), 1354–1363. https://doi.org/10.1245/s10434-022-12863-9
Publication Date
Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., Tabibian, J. H., & Assis, D. N. (2022). AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 77(2), 659–702. https://doi.org/10.1002/hep.32771
Publication Date
Zhang, Y., Xu, H., Cui, G., Liang, B., Chen, X., Ko, S., Affo, S., Song, X., Liao, Y., Feng, J., Wang, P., Wang, H., Xu, M., Wang, J., Pes, G. M., Ribback, S., Zeng, Y., Singhi, A., Schwabe, R. F., … Chen, X. (2022). β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 163(2), 481–494. https://doi.org/10.1053/j.gastro.2022.04.028
Publication Date